NovoCure (NVCR) Depreciation & Amortization (CF) (2014 - 2026)

NovoCure's Depreciation & Amortization (CF) history runs 13 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 24.03% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $15.4 million (up 31.54% YoY), while the FY2025 annual figure was $14.6 million, up 30.4% from the prior year.
• Depreciation & Amortization (CF) came in at $4.1 million for Q1 2026 at NovoCure, down from $4.2 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $4.2 million in Q4 2025 to a low of $2.5 million in Q3 2024.
• A 5-year average of $3.0 million and a median of $2.8 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) fell 12.31% in 2024 and jumped 49.02% in 2025, its largest moves.
• NovoCure's Depreciation & Amortization (CF) stood at $2.7 million in 2022, then advanced by 0.85% to $2.7 million in 2023, then rose by 13.99% to $3.1 million in 2024, then surged by 35.89% to $4.2 million in 2025, then fell by 2.23% to $4.1 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $4.1 million, $4.2 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison